ReviewGastroenterology2018
Epidemiology of Esophageal Squamous Cell Carcinoma.
Review in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07627347 (Clinical Trial on the Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Resectable Esophageal Squamous Cell Carcinoma), which is not on this map. Cited by 1,005 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial on the Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Resectable Esophageal Squamous Cell Carcinoma
Who cites it
1,005 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,701 citations in OpenAlex.
- Immunotherapy in advanced gastroesophageal cancers: A meta-analysis of sex-based outcomes in overall survival.International journal of cancer · 2026Pooled it
- Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons.Advances in therapy · 2026Pooled it
- Associations of PD-L1 expression status, tumor histology and patient ethnic background with immunotherapy outcomes in patients with advanced esophageal cancer.Frontiers in pharmacology · 2026Pooled it
- Pooled it
- PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Trial
- PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- Long-term efficacy and progression patterns of paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced, borderline-resectable esophageal squamous cell carcinoma: results from a phase II NEOCRTEC1601 study.International journal of surgery (London, England) · 2025Trial
- The TRAP complex (SSR1-SSR4): mechanistic roles and therapeutic opportunities.Annals of medicine · 2026Review
- Spatiotemporal co-occurrence patterns and related risk factors of esophageal and lip and oral cavity cancers among older adults across 203 countries and territories: a machine learning-driven systematic analysis.Annals of medicine · 2026Article
- Role of the circadian rhythm in squamous cell carcinoma: From molecular mechanism to therapy (Review).Molecular medicine reports · 2026Review
- High Serum IgA Identifies Poor Responders to Immune Checkpoint Inhibitors in Patients with Unresectable Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2026Article
- Keratinizing squamous cell carcinoma of the distal Esophagus in a young adult woman with celiac disease: a case report.Oxford medical case reports · 2026Article
- Artificial intelligence-based virtual iodine staining model for esophageal squamous cell carcinoma: a multicenter proof-of-concept study.Surgical endoscopy · 2026Article
- ACTB promotes ESCC progression by regulating the AKT-mTOR signaling pathway through an mOncogene · 2026Article
- Article
- Plasma autoantibody profiling via PhIP-seq and machine learning for diagnosis of esophageal squamous cell carcinoma.Nature communications · 2026Observational
- Article
- The role of deubiquitinating enzymes and their inhibitors in esophageal carcinoma (Review).International journal of oncology · 2026Review
- Burden of Esophageal Cancer in Asia in 2022 and Projections for 2050: A Critical Appraisal.Journal of gastroenterology and hepatology · 2026Article
945 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrection.2018
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC) accounts for about 90% of the 456,000 incident esophageal cancers each year. Regions of high incidence include Eastern to Central Asia, along the Rift Valley in East Africa, and into South Africa. There are many causes of ESCC, which vary among regions. Early studies in France associated smoking cigarettes and heavy alcohol consumption with high rates of ESCC, but these factors cannot explain the high incidence in other regions. We discuss other risk factors for ESCC, including polycyclic aromatic hydrocarbons from a variety of sources, high-temperature foods, diet, and oral health and the microbiome-all require further research. A growing list of defined genomic regions affects susceptibility, but large genome-wide association studies have been conducted with ethnic Chinese subjects only; more studies are called for in the rest of Asia and Africa. ESCC has been understudied, but growing infrastructure in more high-incidence countries will allow rapid progress in our understanding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.